An experimental model for the therapy of mouse neuroblastoma

Arima, Eitoku; Byfield, John E.; Finklestein, Jerry Z.; Fonkalsrud, Eric W.

doi:10.1016/0022-3468(73)90418-1

Cited by 16 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neuroblastoma is the second most common solid tumor in children (Voute and de Kraker, 1980), and the prognosis for patients with neuroblastoma has not improved significantly (Pinkel, 1976). We therefore studied whether PGD, effectively destroy mouse neuroblastoma, which is used widely as a model for human neuroblastoma (Arima et al, 1973;Finklestein et al, 1975;Sheffler et al, 1979;West et al, 1980). We report the effects of PGD2 on the morphology of cultured mouse neuroblastoma cells as analyzed at both light and electron microscopic levels.…”

mentioning

confidence: 99%

Cytotoxic action of prostaglandin D₂ on mouse neuroblastoma cells

Higashida¹,

Kano-Tanaka²,

Natsuume‐Sakai³

et al. 1983

Intl Journal of Cancer

View full text Add to dashboard Cite

Addition to the culture medium of prostaglandin (PG) D2 resulted in the degeneration in a dose- and time-dependent manner of N18TG-2 cells cloned from mouse neuroblastoma. The ED50 for PGD2-induced cytotoxicity was about 10 microM. The degenerative changes were irreversible when the cells were exposed for more than 10 h. Scanning and transmission electron microscopic examination revealed that treatment with PGD2 resulted in appearance of numerous blebs of various sizes along the cell surface and also in destruction of surface membrane and of cytoplasmic organelles. Tumor weight of N18TG-2 neuroblastoma inoculated subcutaneously on the backs of A/J mice was about 35-70% less than that of controls after 14 days of single daily i.p. or s.c. injections of 0.5-1 mg/kg of PGD2. The results indicate that PGD2 has growth-inhibitory effects on mouse neuroblastoma cells in vitro and in vivo.

show abstract

mentioning

confidence: 99%

Cytotoxic action of prostaglandin D₂ on mouse neuroblastoma cells

Higashida¹,

Kano-Tanaka²,

Natsuume‐Sakai³

et al. 1983

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Cytoxan and vincristine have been found to have some limited benefit in the chemotherapy of advanced clinical cases of neuroblastoma (Finklestein and Gilchrist, 1972;Finklestein et al, 1973;Arima et al, 1973). In other studies on this model, fractional radiation exposure exhibited a dose-dependent increase in survival time .…”

Section: Discussionmentioning

confidence: 94%

Chemotherapy of a murine neuroblastoma model

Murphy

Williams

Keogh

1975

Journal of Surgical Oncology

View full text Add to dashboard Cite

The C1300 murine neuroblastoma model can be readily maintained by serial passage in A/J mice. Characteristics of the tumor, such as weight of the primary lesion, days of survival after tumor inoculation, or the number of metastatic foci at death, are relatively reproducible and permit experimental evaluation of various modes of treatment, including chemotherapy, that are not possible in man. In the present study, single-dose adriamycin chemotherapy was of significant benefit. Multiple dose treatment was too toxic and lethal. Cytosine arabinoside in various doses was without detectable merit. These results, from an animal model, are of benefit in evaluating further possible drug combinations in ongoing clinical trials seeking to improve the results from chemotherapy in children with advanced neuroblastoma.

show abstract

Studies and characterization of a murine neuroblastoma model

Keogh

Chu

Williams

et al. 1976

Journal of Surgical Oncology

View full text Add to dashboard Cite

Clinical chemotherapy in the treatment of neuroblastoma is undergoing further evaluation. Chemotherapeutic agents, cyclophosphamide, vincristine, and hexamethylmelamine, were investigated in a murine neuroblastoma model that, in part, histologically and morphologically resembles the human tumor. The tumor was inoculated subcutaneously (SC), intramuscularly (IM), intraperitoneally (IP), intrarenally (IR). Growth of tumor was observed at all sites, as well as the appearance of metastases. Maximal survival of 32 +/- 1 days was seen (SC) and the minimum was 15 +/- 1 days (IR) (p less than 0.05). Corresponding survival rate for IM was 26 +/- 1 days and IP 21 +/- 1 days. For this reason SC was selected for drug testing. Cyclophosphamide 100 mg/kg/week showed the most favorable results, as determined by autopsy status with fewer tumors and a greater tumor weight decrease over time. This agent also showed a significantly longer survival in comparison to all other drugs (p less than 0.0001). The results with vincristine and hexamethylmelamine in the dose ranges employed differed little from the placebo, except for the finding of a slight decrease in body weight at autopsy.

show abstract

An experimental model for the therapy of mouse neuroblastoma

Cited by 16 publications

References 6 publications

Cytotoxic action of prostaglandin D₂ on mouse neuroblastoma cells

Cytotoxic action of prostaglandin D₂ on mouse neuroblastoma cells

Chemotherapy of a murine neuroblastoma model

Studies and characterization of a murine neuroblastoma model

Contact Info

Product

Resources

About

An experimental model for the therapy of mouse neuroblastoma

Cited by 16 publications

References 6 publications

Cytotoxic action of prostaglandin D2 on mouse neuroblastoma cells

Cytotoxic action of prostaglandin D2 on mouse neuroblastoma cells

Chemotherapy of a murine neuroblastoma model

Studies and characterization of a murine neuroblastoma model

Contact Info

Product

Resources

About

Cytotoxic action of prostaglandin D₂ on mouse neuroblastoma cells

Cytotoxic action of prostaglandin D₂ on mouse neuroblastoma cells